Lilly Covid drug trial : US pharma giant launches phase 3 trial of baricitinib
Lilly Covid drug trial : Eli Lilly and Company has enrolled the first patient in a phase 3 randomized, double-blind, placebo-controlled trial to assess the ... Read More
AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial
AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in ... Read More
Actemra coronavirus clinical trial : Genentech gets FDA nod for COVID-19 trial
Actemra coronavirus clinical trial : Genentech has been given approval by the US Food & Drug Administration (FDA) to undertake the phase 3 COVACTA trial ... Read More
Blackstone seals deal to acquire AYUMI Pharmaceutical: A strategic move in Japan’s pharma market
Global investment firm Blackstone has announced the acquisition of AYUMI Pharmaceutical, a leading Japanese specialty pharma company, marking its first controlling private equity investment in ... Read More
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to ... Read More
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows the European Commission's recent approval of Hulio ... Read More
Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas
In a significant advancement for biopharmaceuticals, Novartis' division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. ... Read More